Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Beyond Air Inc (XAIR)

NASDAQ
Currency in USD
0.488
-0.008(-2.02%)
Closed
After Hours
0.485-0.003(-0.615%)
XAIR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.4410.493
52 wk Range
0.2962.360
Key Statistics
Edit
Prev. Close
0.496
Open
0.493
Day's Range
0.441-0.493
52 wk Range
0.296-2.36
Volume
634.8K
Average Volume (3m)
701.86K
1-Year Change
-66.69%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XAIR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
2.500
Upside
+412.295%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Beyond Air Inc Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Beyond Air Inc SWOT Analysis


Innovative NO Delivery
Beyond Air's LungFit PH system generates nitric oxide from room air, potentially disrupting the traditional canister-based market with enhanced safety and cost-effectiveness
Financial Tightrope
Explore Beyond Air's strategies to reduce cash burn and reach breakeven by FY2027, while facing revenue projection challenges and the need for additional funding
Market Expansion Plans
Learn about Beyond Air's efforts to broaden LungFit PH's applications, including a transport-compatible system and potential use in cardiac surgeries
Analyst Outlook
Roth Capital Partners maintains a Buy rating with a $2.00 price target, reflecting cautious optimism amidst Beyond Air's execution risks and growth potential
Read full SWOT analysis
XAIR Full Pro Research
Institutional-Grade Stock Analysis
Understand how XAIR earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Beyond Air Inc Earnings Call Summary for Q4/2024

  • Beyond Air reported 60% increase in hospital clients and $0.8M revenue, up from $0.2M YoY, with $13.4M net loss
  • Strategic partnerships formed with Healthcare Links, TrillaMed, and BAC for military, veterans, and international market expansion
  • Company secured $20.6M private placement, extinguished $17.85M loan, and established $11.5M royalty funding agreement
  • FDA reviewing PMA supplement for LungFit PH; company preparing to file another for next-gen system by March 2025
  • Beyond Air expects positive gross margins by March 2024, targeting 60-65% by end of 2025; anticipates uneven revenue growth
Last Updated: 12/11/2024, 10:36 pm
Read Full Transcript

Compare XAIR to Peers and Sector

Metrics to compare
XAIR
Peers
Sector
Relationship
P/E Ratio
−0.6x−4.9x−0.7x
PEG Ratio
−0.02−0.050.00
Price/Book
1.3x1.1x2.6x
Price / LTM Sales
15.0x1.7x3.2x
Upside (Analyst Target)
309.8%136.2%46.6%
Fair Value Upside
Unlock7.0%7.4%Unlock

Analysts' Recommendations

4 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.500

(+412.30% Upside)

People Also Watch

2.1300
RMTI
-2.29%
0.370
WINT
-5.15%
0.9110
TPST
+3.42%
3.580
TNYA
+7.83%
1.270
NUWE
+1.60%

FAQ

What Is the Beyond Air (XAIR) Stock Price Today?

The Beyond Air stock price today is 0.488

What Stock Exchange Does Beyond Air Trade On?

Beyond Air is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Beyond Air?

The stock symbol for Beyond Air is "XAIR."

What Is the Beyond Air Market Cap?

As of today, Beyond Air market cap is 35.23M.

What is Beyond Air Earnings Per Share?

The Beyond Air EPS is -1.37.

What Is the Next Beyond Air Earnings Date?

Beyond Air will release its next earnings report on 05 Feb 2025.

From a Technical Analysis Perspective, Is XAIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.